Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
desmopressin acetate
|
| gptkbp:ATCCode |
gptkb:H01BA02
|
| gptkbp:brand |
gptkb:desmopressin
|
| gptkbp:concentration |
1.5 mg/mL
|
| gptkbp:contraindication |
hyponatremia
hypersensitivity to desmopressin |
| gptkbp:form |
gptkb:nasal_spray
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Ferring_Pharmaceuticals
|
| gptkbp:marketWithdrawalDate |
2020
|
| gptkbp:regulates |
withdrawn
|
| gptkbp:retired |
quality issues with drug potency
|
| gptkbp:routeOfAdministration |
intranasal
|
| gptkbp:sideEffect |
nausea
headache nasal congestion flushing |
| gptkbp:usedFor |
treatment of von Willebrand disease
treatment of hemophilia A |
| gptkbp:bfsParent |
gptkb:desmopressin
|
| gptkbp:bfsLayer |
7
|
| https://www.w3.org/2000/01/rdf-schema#label |
Stimate
|